Related Experiment Video
Updated: Oct 10, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Artificial intelligence, molecular subtyping, biomarkers, and precision oncology
1Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, U.S.A.
Abstract:
A targeted cancer therapy is only useful if there is a way to accurately identify the tumors that are susceptible to that therapy. Thus rapid expansion in the number of available targeted cancer treatments has been accompanied by a robust effort to subdivide the traditional histological and anatomical tumor classifications into molecularly defined subtypes. This review highlights the history of the paired evolution of targeted therapies and biomarkers, reviews currently used methods for subtype identification, and discusses challenges to the implementation of precision oncology as well as possible solutions.
Insights
Precision oncology requires accurate tumor identification for targeted cancer therapies. This review explores the evolution of targeted treatments, biomarker development, and challenges in implementing molecularly defined cancer subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted cancer therapies necessitate precise identification of susceptible tumors.
- The development of targeted treatments has driven the classification of tumors into molecular subtypes.
- Traditional tumor classifications are evolving towards molecularly defined subtypes.
Purpose of the Study:
- To review the co-evolution of targeted therapies and biomarkers.
- To examine current methods for identifying molecular tumor subtypes.
- To discuss challenges and solutions for implementing precision oncology.
Main Methods:
- Literature review of targeted therapies and biomarkers.
- Analysis of current molecular subtype identification techniques.
- Discussion of implementation challenges in precision oncology.
Main Results:
- Paired evolution of targeted therapies and biomarkers is a key trend.
- Various methods exist for molecular subtype identification.
- Significant challenges impede the widespread adoption of precision oncology.
Conclusions:
- Accurate biomarker-driven tumor identification is crucial for effective targeted therapy.
- Overcoming implementation hurdles is essential for advancing precision oncology.
- Continued research into molecular subtypes will refine cancer treatment strategies.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Applications of Molecular Taxonomy
Modern Molecular Taxonomy

